Anyone used 3bp (3-bromopyruvate)?

5093 Posts | Page(s): Prev 12...508 509 510 

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Fri Jul 12, 2019 03:27 PM

Quote | Reply

Dr. Noy, was featured in a recent OncLive article discussing treatment of Burkitt Lymphoma using Devimistat (CPI-613) https://www.onclive.com/web-exclusives/devimistat-could-have

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Sun Jul 14, 2019 01:38 AM

Quote | Reply

critic, the Calitheria and Nektar drugs are exciting! We are approaching the point where powerful FDA approved pharmaceuticals could be available to amplify other metabolic strategies. I am considering what might happen if CB-839 were to be combined with other metabolics. Glutamine, glucose, OXPHOS these are important cancer targets. What happens when all of them could be selectively turned off in cancer cells?

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Sun Jul 14, 2019 06:23 PM

Quote | Reply

There is some news that the thread should be made aware of.                                                                                 Big news.                                                                         The biggest news ever!

It had seemed too quiet to me lately. I have been wondering what's happening with 3-BP? Now we know.

Within the last few days a South Korean company has entered into metabolic cancer treatment; specifically into 3-BP medicine. Apparently, the intention is to move 3-BP formulations into clinical trials over the near term.

The translations are not entirely clear, though from what I understand, 3-BP technology transfer has occurred officially involving a range of cancer indications including breast, liver, bladder and melanoma. The wording is unclear though the intention appears for the technology for other indications to also be transferred.   

The South Korean company made a wise move by apparently bringing on side many of the metabolic thought leaders. It will not be easy to have much of an argument when everyone knowledable about metabolics are already on the team.

It would have been helpful, though, if there had been a simultaneous press release in English through the American based companies (e.g., Ko Discovery). This is how such communications typically are reported. However, I have not seen such a release yet through Ko Discovery. 

It will obviously be extremely interesting to learn how 3-BP thought leaders would approach formulation, patient selection, etc.. 3-BP has had such a lengthy preamble before clinical testing that there could be yet more powerful strategies that have not been reported.

The beta-cyclodextrin 3-BP that Cage Pharma is apparently intending to bring to the clinic certainly looks impressive, though one suspects that those with even deeper mechanistic knowledge of 3-BP could find an even more effective treatment. There has been some notable 3-BP Korean research that might be integrated into a treatment.

5093 Posts | Page(s): Prev 12...508 509 510 
Subscribe to this message board discussion

We care about your feedback. Let us know how we can improve your CancerCompass experience.